Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Oncology

pharma-news-for-regeneron-astrazeneca-syndax

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves PTC’s AADC Gene Therapy; DUPIXENT sBLA Acceptance for Urticaria; CHMP Recommends TAGRISSO for EGFR Lung Cancer; FDA Approves DANZITEN for CML; Syndax Wins FDA Approval for REVUFORJ in Acute Leukemia

Explore More...
Understanding Neuroendocrine Tumors

Understanding Neuroendocrine Tumors (NETs): An In-Depth Look

Neuroendocrine Tumors (NETs) Unraveling the Mystery of a Complex Cancer

Neuroendocrine Tumors (NETs): Unraveling the Mystery of a Complex Cancer

Global Neuroendocrine Tumor Market Outlook

Unveiling the Future: Global Neuroendocrine Tumor Market Trends & Innovations

Pharma-news-for-modalis-pfizer-hibercell

FDA Grants Orphan Status to MDL-101 for LAMA2-CMD; Pfizer’s ABRYSVO Approved for High-Risk Adults (18-59); KIND’s AND017 Gains Orphan Designation for Sickle Cell Disease; HiberCell’s HC-7366 Fast-Tracked for AML; ORLYNVAH Approved for Uncomplicated UTIs

medtech-news-for-endospan-boston-scientific-ge-healthcare

iRhythm’s Zio® AT Device Improvements Receive FDA Clearance; Epitel Adds REMI AI Device to Portfolio with Fourth FDA 510(k); SeaStar Medical Advances Acute Kidney Injury Trial, Approaches Interim Analysis; Endospan Completes Primary Enrollment for TRIOMPHE Study of NEXUS® Stent Graft; Boston Scientific Enhances FARAPULSE™ PFA with New Cardiac Mapping Technology; GE HealthCare Debuts CareIntellect to Support Oncologists with AI-Enhanced Patient Insights

pharma-news-for-gilead-merck-astellas

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

medtech-news-for-roche-bausch-lomb-abbott

Roche Receives FDA Approval for Itovebi; FDA Approves Bausch + Lomb’s Envista® Envy™; Microbot Medical Successfully Completes Pivotal Human Clinical Trial and Accelerates Go-to-Market Strategy for LIBERTY® Launch; Positive FDA Guidance on Phase III Trial of 64Cu-SAR-Bispsma for Recurrent Prostate Cancer; ELEHEAR Launches Hearing Aids at Just $399; Abbott Advances Pulsed Field Ablation Studies and Launches New Technology for Cardiac Mapping

Pharma-news-for-astellas-gsk-astrazeneca

Astellas & AviadoBio’s Exclusive Deal for AVB-101; GSK’s Depemokimab Shows Positive Results for Nasal Polyps; Lilly’s Mirikizumab Outperforms Ustekinumab in Crohn’s Study; TREMFYA Delivers Strong Results in Crohn’s & Colitis; ENHERTU Approved in China for HER2-Mutant NSCLC.

late-stage-prostate-cancer-drugs

12 Breakthrough Prostate Cancer Drugs in Late-Stage Development 

glioma-vs-glioblastoma-therapeutics-space

Glioma vs. Glioblastoma Therapeutics Space: Unveiling the Battlefront

Most asked questions about Glioblastoma multiforme

13 of the most commonly asked questions about Glioblastoma multiforme, Answered

GBM-Market-Glioblastoma-Multiforme-Therapeutic-Advancements

Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition

Glioblastoma Multiforme Market Emerging Pipeline Therapies To Keep A Keen Eye On

Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On

Glioblastoma multiforme Treatment Market GBM Treatment Market

Huge Unmet Needs in the Glioblastoma Multiforme Treatment Market Driving the Market Size Growth

pharma-news-for-bms-palvella-orogen

OPDIVO Approved for Resectable NSCLC; Palvella Gets $2.6M FDA Grant; First Patient Dosed in UGN-103 Bladder Cancer Trial; Recordati Acquires ENJAYMO for $825 Million; AIRSUPRA Reduces Severe Asthma Exacerbations

7-key-companies-developing-trispecific-antibodies

7 Companies at the Forefront of Trispecific Antibody Development

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader